Vaccines for the prevention of respiratory viral infections: problems and current status

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.13.6.681PMID 15174954
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Impact of Three Influenza Epidemics on Primary Care in England and Wales

  2012cited by this paper
• Clinical Virology of Rhinoviruses

  2008cited by this paper
• DNA Vaccines

  2006cited by this paper
• Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza

  2004cited by this paper
• Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution.

  2004cited by this paper
• Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China

  2004cited by this paper
• Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China.

  2004cited by this paper
• Serology of Severe Acute Respiratory Syndrome: Implications for Surveillance and Outcome

  2004cited by this paper
• Aetiology: Koch's postulates fulfilled for SARS virus

  2003cited by this paper
• Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3′ Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and Immunogenicity

  2003cited by this paper
• Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains

  2003cited by this paper
• Mortality associated with influenza and respiratory syncytial virus in the United States.

  2003cited by this paper
• Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection

  2003cited by this paper
• Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults

  2003cited by this paper
• MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

  2003cited by this paper
• Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

  2003cited by this paper
• SARS, mögliche Zoonose im Spannungsfeld tierpathogener Coronaviren

  2003cited by this paper
• [SARS, possible zoonosis in the area of conflict of pathogenic coronaviruses of animals].

  2003cited by this paper
• Lung pathology of fatal severe acute respiratory syndrome

  2003cited by this paper
• Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection.

  2003cited by this paper
• The economic burden of non-influenza-related viral respiratory tract infection in the United States.

  2003cited by this paper
• Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

  2003cited by this paper
• Human Metapneumovirus in Severe Respiratory Syncytial Virus Bronchiolitis

  2003cited by this paper
• Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.

  2003cited by this paper
• Immunostimulating reconstituted influenza virosomes.

  2003cited by this paper
• Development of vaccines against common colds.

  2002cited by this paper
• Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults.

  2002cited by this paper
• Science, medicine, and the future: New vaccine development

  2002cited by this paper
• Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.

  2002cited by this paper
• DIAGNOSIS OF LEGIONELLA INFECTION

  2002cited by this paper
• Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000.

  2001cited by this paper
• Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.

  2001cited by this paper
• Current research on respiratory viral infections: Third International Symposium

  2001cited by this paper
• A newly discovered human pneumovirus isolated from young children with respiratory tract disease

  2001cited by this paper
• A Chimeric Human-Bovine Parainfluenza Virus Type 3 Expressing Measles Virus Hemagglutinin Is Attenuated for Replication but Is Still Immunogenic in Rhesus Monkeys

  2001cited by this paper
• Recombinant Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used To Achieve Simultaneous Mucosal Immunization against RSV and HPIV3

  2001cited by this paper
• Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults.

  2001cited by this paper
• Current research on respiratory viral infections: Fourth International Symposium

  2001cited by this paper
• Principles of Appropriate Antibiotic Use for Acute Pharyngitis in Adults: Background

  2001cited by this paper
• PIV-3 vaccine National Institutes of Health/Aviron.

  2001cited by this paper
• [Development of a novel influenza vaccine derived from a continuous cell line].

  2001cited by this paper
• Respiratory Syncytial Virus Infection in Adults

  2000cited by this paper
• A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.

  2000cited by this paper
• Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes.

  2000cited by this paper
• Humoral and cell-mediated immunity to vero cell-derived influenza vaccine.

  2000cited by this paper
• Rhinoviruses infect the lower airways.

  2000cited by this paper
• DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation.

  2000cited by this paper
• A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines.

  2000cited by this paper
• Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

  2000cited by this paper
• A focus on acute sinusitis in adults: changes in disease management.

  1999cited by this paper
• Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice

  1999cited by this paper
• The economic impact of pandemic influenza in the United States: priorities for intervention.

  1999cited by this paper
• Epidemiological features of parainfluenza virus infections: Laboratory surveillance in England and Wales, 1975–1997

  1999cited by this paper
• Addition of a Missense Mutation Present in the L Gene of Respiratory Syncytial Virus (RSV) cpts530/1030 to RSV Vaccine Candidate cpts248/404 Increases Its Attenuation and Temperature Sensitivity

  1999cited by this paper
• Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine.

  1999cited by this paper
• Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

  1998cited by this paper
• Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.

  1998cited by this paper
• The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

  1998cited by this paper
• Development of a mammalian cell (Vero) derived candidate influenza virus vaccine.

  1998cited by this paper
• DNA vaccines.

  1998cited by this paper
• Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.

  1997cited by this paper
• Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old.

  1997cited by this paper
• Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse

  1997cited by this paper
• Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.

  1997cited by this paper
• The development of cowpea mosaic virus as a potential source of novel vaccines.

  1996cited by this paper
• Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly.

  1996cited by this paper
• Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

  1996cited by this paper
• Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990

  1996cited by this paper
• Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene

  1996cited by this paper
• A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

  1995cited by this paper
• Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

  1995cited by this paper
• Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

  1995cited by this paper
• Amplified rhinovirus colds in atopic subjects

  1994cited by this paper
• Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.

  1994cited by this paper
• A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.

  1994cited by this paper
• Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

  1994cited by this paper
• Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.

  1993cited by this paper
• Incidence of episodes of acute asthma and acute bronchitis in general practice 1976-87.

  1993cited by this paper
• Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

  1993cited by this paper
• Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines.

  1992cited by this paper
• Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.

  1989cited by this paper
• Viral "bronchitis" in childhood: relationship to asthma and obstructive lung disease.

  1988cited by this paper
• A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2.

  1987cited by this paper
• Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers

  1982cited by this paper
• Human responses to two decavalent rhinovirus vaccines.

  1975cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969cited by this paper
• Respiratory Syncytial Virus

  1961cited by this paper

• Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality

  2012cites this paper
• Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus

  2007cites this paper
• Live vaccines for human metapneumovirus designed by reverse genetics

  2006cites this paper